Manufacturing, Cell Therapies

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility

July 16, 2021

The GMP facility is designed to maximize bioprocessing efficiency of newborn stem cells and manufacturing at scale.

Custom Viral Vector Manufacturing Protocols to be Produced by Univercells Technologies and VectorBuilder

July 09, 2021

Univercells Technologies and VectorBuilder to produce custom viral vectors for cell and gene therapies as well as vaccine applications.

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

July 01, 2021

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Catalent to Acquire RheinCell Therapeutics

July 01, 2021

Catalent expands capabilities for stem cell-based therapies with acquisition of RheinCell’s GMP-grade human iPSCs.

Analytical Strategies for Cell and Gene Therapy Development

July 01, 2021

Developing bioassay methods requires a new approach for cell and gene therapy drug development.

CGT Catapult Announces Expansion into Scotland

June 30, 2021

The Cell and Gene Therapy Catapult will establish offices and laboratories in Edinburgh, Scotland.

Genezen Invests in New CGMP Lentiviral Vector Production Facility

June 29, 2021

Genezen Laboratories has broken ground on a new current good manufacturing practice (CGMP)-compliant lentiviral vector production facility.

University of Birmingham Joins Advanced Therapies Skills Training Network

June 24, 2021

The University of Birmingham has been confirmed as the third National Training Centre in the Advanced Therapies Skills Training Network (ATSTN) initiative

Horiba Joins CGT Catapult Consortium to Accelerate Development of PAT

June 18, 2021

Horiba has joined a consortium aimed at accelerating the development of process analytical technologies for cell and gene therapy manufacturing

Yposkesi Launches Project SKY for its Second Commercial Bioproduction Site

June 16, 2021

Yposkesi is building its second commercial facility for cell and gene therapy manufacturing at its campus on Corbeil-Essonnes, France.